Get started
Author

Emmanuelle Verger

Observed names: E Verger, E. Verger, Emanuelle Verger, Emmanuelle VERGER, VERGER, Emmanuelle
Observed institutions: Inserm, Université Paris Cité, Institut National de la Transfusion Sanguine, Assistance Publique – Hôpitaux de Paris, Hôpital Robert-Debré, Centre Hospitalier Universitaire Pointe-à-Pitre, Hôpital Saint-Louis, Université Paris Diderot, Institut de recherche Saint-Louis, Physiologie De L'Axe Gonadotrope, Hématopoïèse normale et pathologique : Emergence, environnement et recherche translationnelle, Institut Universitaire d'Hématologie, Université des Antilles et de la Guyane, Université des Antilles et de la Guyane, Medical University of Vienna
ORCID: 0000-0002-2773-2784
Observed ORCID: 0000-0002-2773-2784
OpenAlex ID: A5041669113
Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network
2015 · Aurélie Caye, Marion Strullu, et al. · Nature Genetics · 194
Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations
2015 · Emmanuelle Verger, Bruno Cassinat, et al. · Blood · 163
Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia
2019 · Nabih Maslah, Norman Salomao, et al. · Haematologica · 133
PDF
The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders
2017 · N Maslah, B Cassinat, et al. · Leukemia · 111
Endothelial Cells Harbouring the JAK2V617F Mutation Display Pro-Adherent and Pro-Thrombotic Features
2018 · Anna Guadall, Elodie Lesteven, et al. · Thrombosis and Haemostasis · 91
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study
2021 · Damien Luque Paz, Jérémie Riou, et al. · Blood Advances · 80
Interferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia
2014 · Bruno Cassinat, Emmanuelle Verger, et al. · New England Journal of Medicine · 77
PDF
Pathophysiological insights in sickle cell disease.
2011 · Marie-Hélène Odièvre, Emmanuelle Verger, et al. · PubMed · 68
Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo
2018 · Emmanuelle Verger, Juliette Soret-Dulphy, et al. · Blood Cancer Journal · 59
PDF
Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses
2020 · Pierre-Edouard Debureaux, Bruno Cassinat, et al. · Blood Advances · 46
PDF
Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification
2023 · Hélène Pasquer, Rafael Daltro de Oliveira, et al. · Leukemia · 40
Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms
2021 · Clémence Marcault, Lin-Pierre Zhao, et al. · Blood · 39
PDF
Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission
2020 · Rafael Daltro De Oliveira, Juliette Soret-Dulphy, et al. · Blood · 39
JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML
2020 · Tracy Dagher, Nabih Maslah, et al. · The Journal of Experimental Medicine · 38
PDF
Quantification of the Mutant CALR Allelic Burden by Digital PCR
2015 · Olivier Mansier, Marina Migeon, et al. · Journal of Molecular Diagnostics · 34
Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin
2020 · Bridget K. Marcellino, Noushin Farnoud, et al. · Blood Advances · 28
Next-generation sequencing for JAK2 mutation testing: advantages and pitfalls
2018 · Nabih Maslah, Emmanuelle Verger, et al. · Annals of Hematology · 27
Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition
2022 · Nabih Maslah, Emmanuelle Verger, et al. · Blood Advances · 24
Clinical Resistance To Ruxolitinib Is More Frequent In Patients Without MPN-Associated Mutations and Is Rarely Due To Mutations In The JAK2 Kinase Drug-Binding Domain
2013 · Annalisa Andreoli, Emmanuelle Verger, et al. · Blood · 21
Hydroxycarbamide stimulates the production of proinflammatory cytokines by endothelial cells: relevance to sickle cell disease
2010 · Sandrine Laurance, François-Xavier Pellay, et al. · Pharmacogenetics and Genomics · 19
Protein Dysregulation in Mouse Hippocampus Polytransgenic for Chromosome 21 Structures in the Down Syndrome Critical Region
2005 · Joo-Ho Shin, Talin Gulesserian, et al. · Journal of Proteome Research · 18
Exacerbation of thromboinflammation by JAK2 V617F mutation worsens the prognosis of cerebral venous sinus thrombosis
2024 · Marie-Charlotte Bourrienne, Véronique Le Cam Duchez, et al. · Blood Advances · 13
JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms
2025 · Nabih Maslah, Nina Kaci, et al. · Nature Communications · 12
PDF
Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70 + v2.0 over MYSEC‐PM
2024 · Matteo Guerra, Hélène Pasquer, et al. · American Journal of Hematology · 11
PDF
Prior exposure of endothelial cells to hydroxycarbamide alters the flow dynamics and adhesion of sickle red blood cells
2014 · Emmanuelle Verger, Damien Schoëvaërt, et al. · Clinical Hemorheology and Microcirculation · 11
Works count: 58
Citation count: 1,482
H-index: 19
I10-index: 27
Year
Topic
Type